Ashleigh Barreto
Contatto Relazioni con gli Investitori presso VIRACTA THERAPEUTICS, INC.
Posizioni attive di Ashleigh Barreto
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Contatto Relazioni con gli Investitori | 01/10/2021 | - |
| Public Communications Contact | 01/10/2021 | - |
Storia della carriera di Ashleigh Barreto
Precedenti posizioni note di Ashleigh Barreto
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Contatto Relazioni con gli Investitori | - | 01/12/2018 |
| Public Communications Contact | - | 01/12/2018 | |
| XOMA CORPORATION | Contatto Relazioni con gli Investitori | - | - |
Statistiche
Distribuzione geografica
| Stati Uniti | 4 |
Posizioni
| Investor Relations Contact | 3 |
| Public Communications Contact | 2 |
Settori
| Health Technology | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| XOMA CORPORATION | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Borsa valori
- Insiders
- Ashleigh Barreto
- Esperienza
